Anzeige
Mehr »
Login
Dienstag, 02.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Ad-hoc: Kursrelevant!? 300%-Steigerung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P2NP ISIN: US83548R1059 Ticker-Symbol: H3D 
Tradegate
01.03.21
21:40 Uhr
1,960 Euro
0,000
0,00 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9201,98012:43

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
16.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
16.02.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update507SONN-1010, fully human IL-12 configured using FHAB platform, Non-Human Primate study informs pharmacokinetic profile Launch of At-The-Market Offering Program for up to $15,875,000 of common stock PRINCETON...
► Artikel lesen
16.02.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quaterly Report4
05.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report10
03.02.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting390PRINCETON, NJ / ACCESSWIRE / February 3, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from...
► Artikel lesen
01.02.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates262The toxicity effects of SON-1010 were well tolerated at doses exceeding levels expected in future human clinical trials, without producing detectable cytokine imbalances SON-1010 (IL12-FHAB) demonstrated...
► Artikel lesen
25.01.Sonnet Bio completes SON-080 toxicology study in monkeys with no adverse effects seen4
25.01.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080604No adverse effects observed at all doses tested Using the results of this study, combined with previously compiled clinical safety data, the Company intends to commence evaluation of human equivalent...
► Artikel lesen
07.01.Breakaway Puck: Sonnet steckt Radeon RX 5700 in eGPU-Box4
06.01.Sonnet eGPU Breakaway Puck: Portables eGPU-Dock mit AMD-Navi-GPU auf MXM-Modul23
17.12.20Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
17.12.20Sonnet BioTherapeutics Holdings, Inc. - 10-K, Annual Report2
17.12.20Sonnet BioTherapeutics reports FY results-
17.12.20Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update333PRINCETON, NJ / ACCESSWIRE / December 17, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
► Artikel lesen
15.12.20Sonnet Breakaway Box 750ex: eGPU-Gehäuse mit 750-Watt-SFX-PSU und Dockingstation2
30.11.20Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010278Compared to recombinant human IL-12, SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile that was similar to IgG antibodies SON-1010 continues to be well tolerated at doses far exceeding...
► Artikel lesen
17.11.20Sonnet unterstützt DACH-Channel mit Youtube-Kanal12
25.08.20Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants584PRINCETON, NJ / ACCESSWIRE / August 25, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...
► Artikel lesen
14.08.20Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update412Company successfully completes warrant repricing and exchange, with gross proceeds to total $10.5 million Company Enters Negotiation for Potential Licensing of Neuropathies Asset PRINCETON, NJ /...
► Artikel lesen
04.08.20Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million375PRINCETON, NJ / ACCESSWIRE / August 4, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...
► Artikel lesen
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1